Article info
PDFORIGINAL ARTICLES
Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors
- Address correspondence and reprint request to: Kiyosumi Shibata, Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466, Japan. Email: shiba{at}med.nagoya-u.ac.jp
Citation
Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors
Publication history
- First published August 1, 2003.
Online issue publication
March 06, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2003 Blackwell Science Ltd.